Verve Therapeutics to Participate in the RBC Capital Markets 2023 Global Healthcare Conference
09 May 2023 - 8:30PM
Verve Therapeutics, a clinical-stage biotechnology company
pioneering a new approach to the care of cardiovascular disease
with single-course gene editing medicines, today announced that
Sekar Kathiresan, M.D., co-founder and chief executive officer,
will participate in a fireside chat during the RBC Capital Markets
2023 Global Healthcare Conference on Tuesday, May 16, 2023 at 9:30
a.m. ET in New York.
A live webcast will be available in the investor section of the
company's website at www.vervetx.com. The webcast will be archived
for 30 days following the presentation.
About Verve Therapeutics Verve
Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage genetic
medicines company pioneering a new approach to the care of
cardiovascular disease, potentially transforming treatment from
chronic management to single-course gene editing medicines. The
company’s initial two programs – VERVE-101 and VERVE-201 – target
genes that have been extensively validated as targets for lowering
low-density lipoprotein cholesterol (LDL-C), a root cause of
cardiovascular disease, in order to durably reduce blood LDL-C
levels. VERVE-101 is designed to permanently turn off the PCSK9
gene in the liver and is being developed initially for heterozygous
familial hypercholesterolemia (HeFH) and ultimately to treat
atherosclerotic cardiovascular disease (ASCVD) patients not at goal
on oral therapy. VERVE-201 is designed to permanently turn off the
ANGPTL3 gene in the liver and is initially being developed in
homozygous familial hypercholesterolemia (HoFH) and ultimately to
treat patients with refractory hypercholesterolemia. For more
information, please visit www.VerveTx.com.
Investor ContactJen RobinsonVerve Therapeutics,
Inc.jrobinson@vervetx.com
Media ContactAshlea
Kosikowski1ABashlea@1abmedia.com
Verve Therapeutics (NASDAQ:VERV)
Historical Stock Chart
From Apr 2024 to May 2024
Verve Therapeutics (NASDAQ:VERV)
Historical Stock Chart
From May 2023 to May 2024